酰基肉碱异常提示新生血管性年龄相关性黄斑变性患者线粒体功能障碍
这项横断面病例对照研究比较了新生血管性AMD患者(n=81)与无其他眼病的白内障对照(n=79)的血浆酰基肉碱浓度。经年龄、性别和吸烟多变量校正后,新生血管性AMD患者的C2-肉碱(乙酰肉碱)水平显著降低(0.810±0.053 vs 1.060±0.053,p=0.002),C18:2-DC肉碱水平显著升高(1.244±0.046 vs 1.013±0.046,p=0.001)。作者认为这些发现提示线粒体功能障碍可能参与新生血管性AMD的发病机制。
要点
- 新生血管性AMD患者血浆C2-肉碱水平显著低于白内障对照。
- 新生血管性AMD患者血浆C18:2-DC肉碱水平显著高于白内障对照。
- 酰基肉碱异常提示线粒体功能障碍可能参与新生血管性AMD发病。
核心结论
- 新生血管性AMD患者血浆C2-肉碱降低、C18:2-DC肉碱升高,提示线粒体功能障碍可能参与其发病机制。
研究设计与样本
- 横断面病例对照研究,病例为新生血管性AMD患者(n=81),对照为无其他眼病的白内障患者(n=79)。
- 参与者于2016至2018年从澳大利亚西悉尼眼科诊所招募,采集血浆后用液相色谱质谱分析酰基肉碱浓度。
- 采用多变量模型对年龄、性别和吸烟进行调整,并用高精度液相色谱-串联质谱确认关键酰基肉碱身份。
主要发现
- 多变量校正后,新生血管性AMD患者C2-肉碱(乙酰肉碱)水平显著低于对照(0.810±0.053 vs 1.060±0.053,p=0.002)。
- 多变量校正后,新生血管性AMD患者C18:2-DC肉碱水平显著高于对照(1.244±0.046 vs 1.013±0.046,p=0.001)。
- 其他检测的酰基肉碱在病例与对照间无显著差异。
关键数值与推荐
- 新生血管性AMD患者C2-肉碱(乙酰肉碱)为0.810±0.053(标准误),对照为1.060±0.053,p=0.002。
- 新生血管性AMD患者C18:2-DC肉碱为1.244±0.046(标准误),对照为1.013±0.046,p=0.001。
临床怎么用
- 血浆酰基肉碱谱可能作为提示新生血管性AMD相关线粒体代谢异常的候选生物标志物,但尚不能用于临床诊断。
- 结果支持在新生血管性AMD发病机制研究中进一步关注线粒体脂肪酸代谢通路。
局限性
- 为横断面病例对照设计,无法确定酰基肉碱异常与新生血管性AMD的因果时序。
- 对照为白内障患者而非完全健康人群,可能引入选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Abnormalities in lipid metabolism are implicated in age-related macular degeneration (AMD), but the pathways involved remain unclear. We assessed whether acylcarnitine concentrations, a marker of lipid and mitochondrial metabolism, differed between patients with AMD and controls. METHODS: In this cross-sectional case-control study, cases (n = 81) had neovascular AMD and controls (n = 79) had cataract with no other ocular pathology. Participants were recruited from eye clinics in Western Sydney, Australia, between 2016 and 2018. Plasma blood samples were collected and liquid chromatography mass spectrometry analyses performed to identify acylcarnitine concentrations. Acylcarnitine levels were adjusted for age, gender and smoking in multivariable models. Confirmation of key acylcarnitine identities was conducted using high mass accuracy liquid chromatography-tandem mass spectrometry. RESULTS: After multivariable adjustment, C2-carnitine (acetylcarnitine) levels were significantly lower in patients with neovascular AMD compared to controls (0.810 ± 0.053 (standard error) compared to 1.060 ± 0.053), p = 0.002). C18:2-DC carnitine (a dicarboxylic acylcarnitine with a 18 carbon side chain and 2 double bonds), levels were significantly higher in patients with neovascular AMD compared to controls (1.244 ± 0.046 compared to 1.013 ± 0.046), p = 0.001). Other acylcarnitines examined were not significantly different between cases and controls. CONCLUSIONS: Reduced plasma levels of C2-carnitine (acetylcarnitine) and increased plasma levels of C18:2-DC carnitine were observed in patients with neovascular AMD compared to controls. These findings suggest mitochondrial dysfunction could be involved in the pathogenesis of neovascular AMD.
引用
- Liew G, Tse B, Ho IV, et al. Acylcarnitine Abnormalities Implicate Mitochondrial Dysfunction in Patients With Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2020. PMID: 38755790. doi:10.1167/iovs.61.8.32
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。